Insiders, Peer Review, Perspective

Path to the top: What kind of experience does it take to get tapped for the helm of a biotech?

We all know the narrative by now: One by one, Big Pharma execs are migrating to biotech in search of a higher level of focus, more direct impact, nimbler operating structure and equity. But is that anecdotal, or a quantifiable trend? What else is notable about this new generation of biotech execs?

Helping sketch that picture, Coulter Partners, a life sciences executive recruitment firm based in London, sifted through 50 of its recent biotech CEO appointments between Europe and the US and offered a glance of the collective profile of this group.

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 42,000+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC
Senior Drug Discovery Oncologist
Schrödinger New York, NY

Visit Endpoints Careers ->